세계의 의료 2차 소견 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)
Medical Second Opinion - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
상품코드:1867553
리서치사:QYResearch
발행일:2025년 10월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 의료 2차 소견 시장 규모는 2024년에 69억 7,300만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 14.8%로 성장하여 2031년까지 179억 4,800만 달러로 확대될 것으로 예측됩니다.
의료 세컨드오피니언은 환자가 초기 진단이나 치료 방침을 제안받은 후, 독립적인 자격을 갖춘 의료 전문가에게 재평가를 의뢰하는 전문 의료 서비스를 말합니다. 여기에는 진단 내용, 치료 계획, 수술의 필요성 등에 대한 검토가 포함될 수 있습니다. 본 서비스는 특히 중증질환, 희귀질환, 복잡한 치료적 개입을 수반하는 사례에서 원격진료, 온라인 플랫폼, 국제협력을 통해 제공되는 것이 일반적입니다. 오진 감소, 치료 정확도 향상, 환자의 신뢰 구축을 목표로 하고 있습니다. 원격 의료의 발전, 세계 의료 협력, AI 기반 진단 기술의 발전과 함께 의료 세컨드 오피니언은 프리미엄 의료 서비스, 보험 서비스, 국경 간 의뢰 생태계에서 중요한 구성 요소로 부상하고 있습니다.
의료 판단이 복잡해짐에 따라 의료 세컨드 오피니언 서비스 시장은 빠르게 성장하고 있습니다. 연례 보고서에 따르면, 전 세계 고소득층과 중산층은 특히 종양학, 심혈관 질환, 희귀질환에서 확인 및 최적화 된 치료 계획을 원하는 환자가 증가하고 있으며, 프리미엄 의료 자원에 대한 접근을 점점 더 많이 요구하고 있습니다. 보험사들은 중대질병보험과 건강보험 상품에 세컨드 오피니언 서비스를 도입하여 고객 참여와 충성도를 높이고 있습니다. 미국, 독일, 싱가포르 등의 정부에서는 세컨드 오피니언을 상환 제도나 법적 프레임워크에 포함시켜 신뢰성을 높이고 있습니다. 한편, AI 지원 진단, 국제 원격 의료 플랫폼, 세계 의료 전문가 네트워크의 통합으로 이러한 서비스의 접근성과 정확성이 크게 향상되었습니다.
의료 세컨드 오피니언 서비스는 관심 증가에도 불구하고 제도적, 운영적 장벽에 직면해 있습니다. 국경을 초월한 서비스 제공은 다양한 의료 시스템, 표준화되지 않은 의료 기록, 데이터 상호운용성 문제로 인해 복잡해지고 있습니다. 고급 의료 전문 지식은 여전히 소수의 상위 기관에 집중되어 있어 공급 측면의 확장성을 제한하고 있습니다. 많은 지역에서 지불 메커니즘이 불분명하고, 보험 적용 범위도 보급을 뒷받침하기에 충분하지 않습니다. 또한, 국경 간 데이터 공유에 있어 데이터 프라이버시 및 규제 준수에 대한 우려는 법적 위험을 초래합니다. 신흥 의료 서비스 제공업체에게는 자격을 갖춘 의사와의 신뢰 네트워크 구축, 일관된 서비스 품질 확보, 병원과의 파트너십 형성은 중요하면서도 어려운 과제입니다.
맞춤형 의료의 발전과 환자 권한 부여를 배경으로 세컨드 오피니언 서비스는 틈새 프리미엄 부가 서비스에서 임상 진료의 표준 구성 요소로 진화하고 있습니다. "특히 암, 심혈관질환, 신경질환에서 '진단+전문가 리뷰'를 통합한 패키지가 확산되고 있습니다. 디지털 헬스 플랫폼과 원격 의료 제공업체들은 AI 이미지 분석, 자동화된 구조화된 의료 기록, 국제 전문가에 대한 접근 등 광범위한 에코시스템에 세컨드 오피니언 기능을 통합하고 있습니다. 아시아, 중동 등 급성장 지역에서는 부유층과 중대질병 보험 가입자가 도입을 주도하고 있으며, 이는 업계를 보다 높은 수준의 개인화, 세계화, 플랫폼형 모델로 이끌고 있습니다.
이 보고서는 세계 의료 세컨드 오피니언 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총매출액, 주요 기업의 시장 점유율과 순위에 초점을 맞추어 지역별, 국가별, 유형별, 용도별 의료용 세컨드 오피니언 분석을 제공합니다.
의료용 세컨드 오피니언 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하여 매출액으로 제시합니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 위치를 분석하고, 의료 세컨드 오피니언에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
HCA Hospitals
AXA PPP Healthcare
Royal London Group
Helsana Group
Cleveland Clinic
Amradnet
Best Doctors
Inova Care
Toranomon Hospital
Keio University Hospital
Johns Hopkins Medicine
Penn Medicine
Oncology International Pvt. Ltd.
GrandOpinion
London Pain Clinic
Mondial Assistance
Medisense
Medo Asia Sdn. Bhd.
유형별 부문
병원
의료 2차 소견 제공 기업
건강보험사
용도별 부문
암
당뇨병
심장질환
신경질환
안과질환
기타
지역별
북미
미국
캐나다
아시아태평양
중국
일본
한국
동남아시아
인도
호주
기타 아시아태평양
유럽
독일
프랑스
영국
이탈리아
네덜란드
북유럽 국가
기타 유럽
라틴아메리카
멕시코
브라질
기타 라틴아메리카
중동 및 아프리카
튀르키예
사우디아라비아
아랍에미리트(UAE)
기타 중동 및 아프리카
LSH
영문 목차
영문목차
The global market for Medical Second Opinion was estimated to be worth US$ 6973 million in 2024 and is forecast to a readjusted size of US$ 17948 million by 2031 with a CAGR of 14.8% during the forecast period 2025-2031.
Medical Second Opinion refers to a professional healthcare service where a patient, after receiving an initial diagnosis or treatment recommendation, consults an independent, qualified medical expert for a reevaluation. This may include a review of diagnosis, therapeutic plan, or surgical necessity. The service is typically delivered through remote consultations, online platforms, or international collaborations, especially in cases involving critical illness, rare diseases, or complex interventions. It aims to reduce misdiagnosis, enhance treatment accuracy, and build patient confidence. With the advancement of telemedicine, global healthcare connectivity, and AI-driven diagnostics, Medical Second Opinion is emerging as a critical component in premium healthcare offerings, insurance services, and cross-border referral ecosystems.
As medical decisions become more complex, the market for Medical Second Opinion services is experiencing rapid growth. According to annual reports, global high-net-worth and middle-class populations are increasingly seeking access to premium healthcare resources, especially in oncology, cardiovascular diseases, and rare conditions where patients demand confirmation and optimized treatment plans. Insurance providers are embedding second opinion services into critical illness and health insurance products, improving customer engagement and loyalty. Governments in countries like the U.S., Germany, and Singapore have incorporated second opinions into reimbursement or legal frameworks, enhancing credibility. Meanwhile, the integration of AI-assisted diagnostics, international telemedicine platforms, and global medical expert networks has significantly improved the accessibility and accuracy of these services.
Despite growing interest, Medical Second Opinion services face systemic and operational barriers. Cross-border service delivery is complicated by diverse healthcare systems, lack of standardized medical records, and data interoperability issues. High-level medical expertise remains concentrated in a few top institutions, limiting supply-side scalability. In many regions, payment mechanisms are unclear, and insurance coverage is insufficient to support widespread adoption. Additionally, concerns about data privacy and regulatory compliance for cross-border data sharing pose legal risks. For emerging providers, building trust networks of qualified physicians, ensuring consistent service quality, and forming hospital partnerships are critical but challenging.
Driven by the rise of personalized medicine and patient empowerment, Medical Second Opinion services are evolving from a niche premium add-on to a standard component of clinical care. Integrated packages offering "diagnosis + expert review" are gaining popularity, particularly for cancers, cardiovascular, and neurological diseases. Digital health platforms and telemedicine providers are embedding second opinion modules into broader ecosystems that include AI imaging analysis, auto-structured medical records, and access to international experts. In fast-growing regions such as Asia and the Middle East, high-net-worth individuals and critical illness policyholders are fueling adoption, pushing the industry toward greater personalization, globalization, and platform-based models.
This report aims to provide a comprehensive presentation of the global market for Medical Second Opinion, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Medical Second Opinion by region & country, by Type, and by Application.
The Medical Second Opinion market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medical Second Opinion.
Market Segmentation
By Company
HCA Hospitals
AXA PPP Healthcare
Royal London Group
Helsana Group
Cleveland Clinic
Amradnet
Best Doctors
Inova Care
Toranomon Hospital
Keio University Hospital
Johns Hopkins Medicine
Penn Medicine
Oncology International Pvt. Ltd.
GrandOpinion
London Pain Clinic
Mondial Assistance
Medisense
Medo Asia Sdn. Bhd.
Segment by Type
Hospitals
Medical Second Opinion Providing Companies
Health Insurance Companies
Segment by Application
Cancer
Diabetes
Cardiac Disorders
Neurological Disorders
Ocular Disorders
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Medical Second Opinion company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Medical Second Opinion in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Medical Second Opinion in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Medical Second Opinion Product Introduction
1.2 Global Medical Second Opinion Market Size Forecast (2020-2031)
1.3 Medical Second Opinion Market Trends & Drivers
1.3.1 Medical Second Opinion Industry Trends
1.3.2 Medical Second Opinion Market Drivers & Opportunity
1.3.3 Medical Second Opinion Market Challenges
1.3.4 Medical Second Opinion Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Medical Second Opinion Players Revenue Ranking (2024)
2.2 Global Medical Second Opinion Revenue by Company (2020-2025)
2.3 Key Companies Medical Second Opinion Manufacturing Base Distribution and Headquarters
2.4 Key Companies Medical Second Opinion Product Offered
2.5 Key Companies Time to Begin Mass Production of Medical Second Opinion
2.6 Medical Second Opinion Market Competitive Analysis
2.6.1 Medical Second Opinion Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Medical Second Opinion Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medical Second Opinion as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hospitals
3.1.2 Medical Second Opinion Providing Companies
3.1.3 Health Insurance Companies
3.2 Global Medical Second Opinion Sales Value by Type
3.2.1 Global Medical Second Opinion Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Medical Second Opinion Sales Value, by Type (2020-2031)
3.2.3 Global Medical Second Opinion Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Diabetes
4.1.3 Cardiac Disorders
4.1.4 Neurological Disorders
4.1.5 Ocular Disorders
4.1.6 Others
4.2 Global Medical Second Opinion Sales Value by Application
4.2.1 Global Medical Second Opinion Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Medical Second Opinion Sales Value, by Application (2020-2031)
4.2.3 Global Medical Second Opinion Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Medical Second Opinion Sales Value by Region
5.1.1 Global Medical Second Opinion Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Medical Second Opinion Sales Value by Region (2020-2025)
5.1.3 Global Medical Second Opinion Sales Value by Region (2026-2031)
5.1.4 Global Medical Second Opinion Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Medical Second Opinion Sales Value, 2020-2031
5.2.2 North America Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Medical Second Opinion Sales Value, 2020-2031
5.3.2 Europe Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Medical Second Opinion Sales Value, 2020-2031
5.4.2 Asia Pacific Medical Second Opinion Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Medical Second Opinion Sales Value, 2020-2031
5.5.2 South America Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Medical Second Opinion Sales Value, 2020-2031
5.6.2 Middle East & Africa Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Medical Second Opinion Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Medical Second Opinion Sales Value, 2020-2031
6.3 United States
6.3.1 United States Medical Second Opinion Sales Value, 2020-2031
6.3.2 United States Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Medical Second Opinion Sales Value, 2020-2031
6.4.2 Europe Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Medical Second Opinion Sales Value, 2020-2031
6.5.2 China Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.5.3 China Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Medical Second Opinion Sales Value, 2020-2031
6.6.2 Japan Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Medical Second Opinion Sales Value, 2020-2031
6.7.2 South Korea Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Medical Second Opinion Sales Value, 2020-2031
6.8.2 Southeast Asia Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Medical Second Opinion Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Medical Second Opinion Sales Value, 2020-2031
6.9.2 India Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
6.9.3 India Medical Second Opinion Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 HCA Hospitals
7.1.1 HCA Hospitals Profile
7.1.2 HCA Hospitals Main Business
7.1.3 HCA Hospitals Medical Second Opinion Products, Services and Solutions
7.1.4 HCA Hospitals Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.1.5 HCA Hospitals Recent Developments
7.2 AXA PPP Healthcare
7.2.1 AXA PPP Healthcare Profile
7.2.2 AXA PPP Healthcare Main Business
7.2.3 AXA PPP Healthcare Medical Second Opinion Products, Services and Solutions
7.2.4 AXA PPP Healthcare Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.2.5 AXA PPP Healthcare Recent Developments
7.3 Royal London Group
7.3.1 Royal London Group Profile
7.3.2 Royal London Group Main Business
7.3.3 Royal London Group Medical Second Opinion Products, Services and Solutions
7.3.4 Royal London Group Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.3.5 Royal London Group Recent Developments
7.4 Helsana Group
7.4.1 Helsana Group Profile
7.4.2 Helsana Group Main Business
7.4.3 Helsana Group Medical Second Opinion Products, Services and Solutions
7.4.4 Helsana Group Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.4.5 Helsana Group Recent Developments
7.5 Cleveland Clinic
7.5.1 Cleveland Clinic Profile
7.5.2 Cleveland Clinic Main Business
7.5.3 Cleveland Clinic Medical Second Opinion Products, Services and Solutions
7.5.4 Cleveland Clinic Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.5.5 Cleveland Clinic Recent Developments
7.6 Amradnet
7.6.1 Amradnet Profile
7.6.2 Amradnet Main Business
7.6.3 Amradnet Medical Second Opinion Products, Services and Solutions
7.6.4 Amradnet Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.6.5 Amradnet Recent Developments
7.7 Best Doctors
7.7.1 Best Doctors Profile
7.7.2 Best Doctors Main Business
7.7.3 Best Doctors Medical Second Opinion Products, Services and Solutions
7.7.4 Best Doctors Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.7.5 Best Doctors Recent Developments
7.8 Inova Care
7.8.1 Inova Care Profile
7.8.2 Inova Care Main Business
7.8.3 Inova Care Medical Second Opinion Products, Services and Solutions
7.8.4 Inova Care Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.8.5 Inova Care Recent Developments
7.9 Toranomon Hospital
7.9.1 Toranomon Hospital Profile
7.9.2 Toranomon Hospital Main Business
7.9.3 Toranomon Hospital Medical Second Opinion Products, Services and Solutions
7.9.4 Toranomon Hospital Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.9.5 Toranomon Hospital Recent Developments
7.10 Keio University Hospital
7.10.1 Keio University Hospital Profile
7.10.2 Keio University Hospital Main Business
7.10.3 Keio University Hospital Medical Second Opinion Products, Services and Solutions
7.10.4 Keio University Hospital Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.10.5 Keio University Hospital Recent Developments
7.11 Johns Hopkins Medicine
7.11.1 Johns Hopkins Medicine Profile
7.11.2 Johns Hopkins Medicine Main Business
7.11.3 Johns Hopkins Medicine Medical Second Opinion Products, Services and Solutions
7.11.4 Johns Hopkins Medicine Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.11.5 Johns Hopkins Medicine Recent Developments
7.12 Penn Medicine
7.12.1 Penn Medicine Profile
7.12.2 Penn Medicine Main Business
7.12.3 Penn Medicine Medical Second Opinion Products, Services and Solutions
7.12.4 Penn Medicine Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.12.5 Penn Medicine Recent Developments
7.13 Oncology International Pvt. Ltd.
7.13.1 Oncology International Pvt. Ltd. Profile
7.13.2 Oncology International Pvt. Ltd. Main Business
7.13.3 Oncology International Pvt. Ltd. Medical Second Opinion Products, Services and Solutions
7.13.4 Oncology International Pvt. Ltd. Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.13.5 Oncology International Pvt. Ltd. Recent Developments
7.14 GrandOpinion
7.14.1 GrandOpinion Profile
7.14.2 GrandOpinion Main Business
7.14.3 GrandOpinion Medical Second Opinion Products, Services and Solutions
7.14.4 GrandOpinion Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.14.5 GrandOpinion Recent Developments
7.15 London Pain Clinic
7.15.1 London Pain Clinic Profile
7.15.2 London Pain Clinic Main Business
7.15.3 London Pain Clinic Medical Second Opinion Products, Services and Solutions
7.15.4 London Pain Clinic Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.15.5 London Pain Clinic Recent Developments
7.16 Mondial Assistance
7.16.1 Mondial Assistance Profile
7.16.2 Mondial Assistance Main Business
7.16.3 Mondial Assistance Medical Second Opinion Products, Services and Solutions
7.16.4 Mondial Assistance Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.16.5 Mondial Assistance Recent Developments
7.17 Medisense
7.17.1 Medisense Profile
7.17.2 Medisense Main Business
7.17.3 Medisense Medical Second Opinion Products, Services and Solutions
7.17.4 Medisense Medical Second Opinion Revenue (US$ Million) & (2020-2025)
7.17.5 Medisense Recent Developments
7.18 Medo Asia Sdn. Bhd.
7.18.1 Medo Asia Sdn. Bhd. Profile
7.18.2 Medo Asia Sdn. Bhd. Main Business
7.18.3 Medo Asia Sdn. Bhd. Medical Second Opinion Products, Services and Solutions
7.18.4 Medo Asia Sdn. Bhd. Medical Second Opinion Revenue (US$ Million) & (2020-2025)